Eli Lilly & Co. (LLY)
1161.13
+1.13
(+0.10%)
USD |
NYSE |
Sep 02, 13:18
Eli Lilly Research and Development Expense (TTM) : 14.60B for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 14.60B |
| March 31, 2026 | 14.11B |
| December 31, 2025 | 13.34B |
| September 30, 2025 | 12.56B |
| June 30, 2025 | 11.83B |
| March 31, 2025 | 11.20B |
| December 31, 2024 | 10.99B |
| September 30, 2024 | 10.53B |
| June 30, 2024 | 10.21B |
| March 31, 2024 | 9.851B |
| December 31, 2023 | 9.313B |
| September 30, 2023 | 8.747B |
| June 30, 2023 | 8.140B |
| March 31, 2023 | 7.566B |
| December 31, 2022 | 7.191B |
| September 30, 2022 | 7.154B |
| June 30, 2022 | 7.060B |
| March 31, 2022 | 6.951B |
| December 31, 2021 | 7.026B |
| September 30, 2021 | 6.904B |
| June 30, 2021 | 6.661B |
| March 31, 2021 | 6.378B |
| December 31, 2020 | 6.086B |
| September 30, 2020 | 5.829B |
| June 30, 2020 | 5.745B |
| Date | Value |
|---|---|
| March 31, 2020 | 5.757B |
| December 31, 2019 | 5.595B |
| September 30, 2019 | 5.405B |
| June 30, 2019 | 5.305B |
| March 31, 2019 | 5.174B |
| December 31, 2018 | 5.051B |
| September 30, 2018 | 5.133B |
| June 30, 2018 | 5.171B |
| March 31, 2018 | 5.151B |
| December 31, 2017 | 5.282B |
| September 30, 2017 | 5.259B |
| June 30, 2017 | 5.176B |
| March 31, 2017 | 5.261B |
| December 31, 2016 | 5.244B |
| September 30, 2016 | 5.238B |
| June 30, 2016 | 5.144B |
| March 31, 2016 | 4.978B |
| December 31, 2015 | 4.796B |
| September 30, 2015 | 4.538B |
| June 30, 2015 | 4.638B |
| March 31, 2015 | 4.664B |
| December 31, 2014 | 4.734B |
| September 30, 2014 | 5.023B |
| June 30, 2014 | 5.158B |
| March 31, 2014 | 5.292B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Johnson & Johnson | 15.06B |
| Merck & Co., Inc. | 27.26B |
| Pfizer Inc. | 10.82B |
| Bristol Myers Squibb Co. | 9.548B |
| Atai Beckley, Inc. | 79.04M |